莫西沙星治疗慢性阻塞性肺疾病急性加重疗效分析

Efficacy analysis of Moxifloxacin in the treatment of acute exacerbation of chronic obstructive pulmonary disease

目的:分析慢性阻塞性肺疾病急性加重患者经莫西沙星治疗的疗效。方法:查阅2013年3月至2014年3月我院呼吸科收治的AECOPD患者病志,分为莫西沙星治疗组(64例)和其他抗生素治疗组(87例)。记录治疗前后患者症状体征,血常规、尿常规、肝骨功能、血气分析以及痰涂片痰培养等检查检验结果以及预后等情况。根据抗菌药物疗效判定标准进行疗效判定。结果:A组痊愈26例(40.62%),显效29例(45.31%),好转6例(9.38%),无效3例(4.69%);有效率85.93%。B组痊愈27例(31.03%),显效42例(48.28%),好转12例(13.79%),无效6例(6.90%);有效率79.31%。A组有效率高于B组,差异有统计学意义。结论:莫西沙星用于COPD急性加重无铜绿假单孢菌感染危险因素患者的初始经验治疗是有效安全的。

Objective： To assess the effectiveness of moxifloxacin in the treatment of acute exacerbation of chronic obstructive pulmonary disease using retrospective analysis. Methods： We consulted the medical records of patients treated by Department of respiration without ICU treatments in our hospital from January 2012 to March 2013. The patients were divided into two groups： Group A patients were treated by Moxifloxa^in while Group B were treated by other antibiotics. The patients＇ symptoms and signs, examination results such as blood test, urine test, functions of liver and kidney, blood gas analysis, sputum smear and sputum culture and prognosis have been recorded, including before and after treatment. Treatment efficacy was determined according Antimierobial Efficacy Criteria. Result： Of all the 64 patients in Group A, 26 cases were recovered（40.63%）, 29 were markedly effective （45.31%）, 6 cases were improved （9.38%）, 3 were invalid （4.69%） ,the general efficiency is 85.93% ; ofaU the 87 patients in Group B, 27 cases were recovered （31.03 %）, 42 were markedly effective （48.28 %）, 12 cases were improved（ 13.79% ）, 6 cases were invalid （6.9%）, the general efficiency is 79.31%. Group A has a higher effective rate than B, no significant difference was observed among the two groups..Conclusion： Moxifloxacin is effective and safe in the initial empirical treatment of AECOPD patients without the hazard of infection of psendomonas aeruginosa.